Avacta Group has been featured on BBC Look North. Our Chief Executive Officer Alastair Smith gave a brief interview, explaining to the BBC the oncology work being undertaken. Avacta Group
In this short video, Avacta’s Chief Executive Officer Alastair Smith provides an update and more information on the recent collaboration and licence agreement with AffyXell… Avacta Group Plc (LON:AVCT) offers reagents and
Avacta Group plc (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss an agreement with AffyXell in S Korea. Alastair talks us through the details, explains the main focus for AffyXell
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, today announced that it has signed a collaboration and license agreement with AffyXell Therapeutics, the recently established joint venture with Daewoong Pharmaceutical ,
In this short video, Avacta’s Chief Executive Officer Alastair Smith explains the TMAC® drug conjugate and the recent data from the lead molecule in that programme. Avacta Group Plc (LON:AVCT) offers
Avacta Group (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the successful initial proof-of-concept for a proprietary new class of anti-cancer therapy. Alastair explains what a TMAC drug conjugate is,
Avacta Group’s Alastair Smith discusses their latest trading update, increase in revenues, better cash position and the outlook for 2020 in this exclusive interview with DirectorsTalk.
Avacta Group (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced that it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, “TMACTM“, in a preclinical animal
Antibodies have been the most popular method for studying protein expression and function for the past decades, but have been dogged by lack of validation and the poor cost-effectiveness of
Avacta plc (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss its trading update for the 17 month period ended 31 December 2019. Alastair explains why its a 17 month reporting
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
